Twitter Updates

    follow me on Twitter

    Monday, February 1, 2010


    The antitumor drug rapamycin targets TOR, a kinase that is part of the PI3K–AKT–mTOR cascade, involved in regulating protein translation, cell growth and autophagy. Reducing TOR function is known to extend the life of yeast, worms and flies.
    Now experiments replicated in three different laboratories demonstrate that rapamycin, fed to male and female mice in a dose that substantially inhibits TOR signalling, can extend their median and maximal lifespan by up to 14%. This life extension was observed in mice fed rapamycin from 270 days of age and also at a late stage in their life, from age 600 days.

    These findings point to the TOR pathway as a critical point in the control of ageing in mammals and in the pathogenesis of late-life illnesses. The small molecule rapamycin, already approved for clinical use for various human disorders, has been found to significantly increase lifespan in mice.

    Is this a step towards an anti-ageing drug for people?
    From Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
    David E. Harrison, et al.doi:10.1038/nature08221

    Please remember, as with all our articles we provide information, not medical advice.
    For any treatment of your own medical condition you must visit your local doctor, with or without our article[s]. These articles are not to be taken as individual medical advice.

    Deepen your understanding of "medical malpractice"...

    For more health info and links visit the author's web site

    No comments:

    Post a Comment